Hematopoietic Cell Transplantation for Autoimmune Diseases: A Review of History, Current State, and Future Issues

Resnick, Igor B.; Metodiev, Krassimir; Lazarova, P.

doi:10.5772/67604

Cited by 3 publications

(3 citation statements)

References 111 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings can potentially change the management of chronic wounds and our view of wound management in general [41,58]. Stem cells are notable due to their vast potential in solving problems of current medicine, including wound healing [45, 59-62], diseases of the nervous system [63][64][65][66][67], diabetes mellitus [68,69], Crohn's disease [70], chronic myeloid leukemia [71,72], heart failure [73,74], liver cirrhosis [75,76] and others.…”

Section: Wound Healingmentioning

confidence: 99%

The application of human Wharton's jelly mesenchymal stem cells in wound healing: A narrative review

Rezaee

Sadeghi

Soleymanha

et al. 2022

jcbior

View full text Add to dashboard Cite

Management and treatment of chronic wounds remain a significant problem in clinical practice. Stem cell therapies are an important and promising approach for regenerative medicine because of their selfrenewal and differentiation potential. Mesenchymal stem cells (MSCs), a major cellular source for regeneration, are present in almost all tissues. The use of embryonic stem cells is morally controversial because of the need to nurture and destroy embryonic cells. Therefore, adult umbilical cord tissues are of particular importance as an alternative source of perinatal tissues. Wharton Jelly is a gelatinous connective tissue in the umbilical cord containing MSCs that can differentiate into osteogenic, adipose, chondrogenic, and other lineages. These cells do not express the MHC-II molecule and show immunomodulatory properties that make them viable for allogeneic and xenogenic transplants in cell therapy. Therefore, the umbilical cord, especially the part named Wharton's jelly, is an important and promising source of mesenchymal stem cells.

show abstract

Section: Wound Healingmentioning

confidence: 99%

The application of human Wharton's jelly mesenchymal stem cells in wound healing: A narrative review

Rezaee

Sadeghi

Soleymanha

et al. 2022

jcbior

View full text Add to dashboard Cite

show abstract

“…In other words, stem cell transplantation has developed as a new way to salvation from different life-threatening autoimmune diseases. Indeed, cell therapy can be effective by preventing the abnormal functioning of self-activated immune cells with the help of safe and effective immune tolerance formed by transplanted cells (Rosa et al 2007 ; Resnick et al 2017 ; Del Papa et al 2018 ; Dazzi et al 2007 ; Radbruch and Thiel 2004 ). Among the various cells, mesenchymal stem cells (MSCs) (obtained from diverse tissues) are mostly known as perfect agents to the regenerative objects to represent cell multi-potency along with anti-inflammatory and powerful regenerating qualities (Larijani et al 2015 ; Han et al 2019 ; Pittenger et al 2019 ; Goodarzi et al 2018a ; Goodarzi et al 2019a ).…”

Section: Introductionmentioning

confidence: 99%

Mesenchymal stem cell as a novel approach to systemic sclerosis; current status and future perspectives

et al. 2020

View full text Add to dashboard Cite

Systemic sclerosis is a rare chronic autoimmune disease with extensive microvascular injury, damage of endothelial cells, activation of immune responses, and progression of tissue fibrosis in the skin and various internal organs. According to epidemiological data, women’s populations are more susceptible to systemic sclerosis than men. Until now, various therapeutic options are employed to manage the symptoms of the disease. Since stem cell-based treatments have developed as a novel approach to rescue from several autoimmune diseases, it seems that stem cells, especially mesenchymal stem cells as a powerful regenerative tool can also be advantageous for systemic sclerosis treatment via their remarkable properties including immunomodulatory and anti-fibrotic effects. Accordingly, we discuss the contemporary status and future perspectives of mesenchymal stem cell transplantation for systemic sclerosis.

show abstract

“…Mixed hematopoietic chimerism is the state of coexistence of donor- and recipient-derived hematopoietic cells in the host. Establishment of such chimerism, via allogeneic bone marrow transplantation (BMT), is a robust method for generating donor-specific tolerance to donor tissue/organs without the need for lifelong immunosuppression ( 1 – 7 ), and it can be used to treat severe autoimmune diseases ( 8 , 9 ). However, its clinical application is dampened by the toxicity of current recipient conditioning regimens.…”

Section: Introductionmentioning

confidence: 99%

Stability of Chimerism in Non-Obese Diabetic Mice Achieved By Rapid T Cell Depletion Is Associated With High Levels of Donor Cells Very Early After Transplant

et al. 2018

View full text Add to dashboard Cite

Stable mixed hematopoietic chimerism is a robust method for inducing donor-specific tolerance with the potential to prevent rejection of donor islets in recipients with autoimmune type-1 diabetes. However, with reduced intensity conditioning, fully allogeneic chimerism in a tolerance resistant autoimmune-prone non-obese diabetic (NOD) recipient has rarely been successful. In this setting, successful multilineage chimerism has required either partial major histocompatability complex matching, mega doses of bone marrow, or conditioning approaches that are not currently clinically feasible. Irradiation free protocols with moderate bone marrow doses have not generated full tolerance; donor skin grafts were rejected. We tested whether more efficient recipient T cell depletion would generate a more robust tolerance. We show that a combination of donor-specific transfusion-cyclophosphamide and multiple T cell depleting antibodies could induce stable high levels of fully allogeneic chimerism in NOD recipients. Less effective T cell depletion was associated with instability of chimerism. Stable chimeras appeared fully donor-specific tolerant, with clonal deletion of allospecific T cells and acceptance of donor skin grafts, while recovering substantial immunocompetence. The loss of chimerism months after transplant was significantly associated with a lower level of chimerism and donor T cells within the first 2 weeks after transplant. Thus, rapid and robust recipient T cell depletion allows for stable high levels of fully allogeneic chimerism and robust donor-specific tolerance in the stringent NOD model while using a clinically feasible protocol. In addition, these findings open the possibility of identifying recipients whose chimerism will later fail, stratifying patients for early intervention.

show abstract

Hematopoietic Cell Transplantation for Autoimmune Diseases: A Review of History, Current State, and Future Issues

Cited by 3 publications

References 111 publications

The application of human Wharton's jelly mesenchymal stem cells in wound healing: A narrative review

The application of human Wharton's jelly mesenchymal stem cells in wound healing: A narrative review

Mesenchymal stem cell as a novel approach to systemic sclerosis; current status and future perspectives

Stability of Chimerism in Non-Obese Diabetic Mice Achieved By Rapid T Cell Depletion Is Associated With High Levels of Donor Cells Very Early After Transplant

Contact Info

Product

Resources

About